Want to see SLGL full AI Analyst Report?
SLGL Stock Chart & Stats
$81.72
-$2.13(-2.60%)
At close: 4:00 PM EDT
$81.72
-$2.13(-2.60%)
Day’s Range― - ―
52-Week Range$23.15 - $97.97
Previous Close$79.83
Volume47.21K
Average Volume (3M)64.39K
Market Cap
$226.50M
Enterprise Value$195.32
Total Cash (Recent Filing)$30.47M
Total Debt (Recent Filing)$1.39M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Nov 05, 2026EPS Estimate
-2.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.97
Shares Outstanding3,273,999
10 Day Avg. Volume71,990
30 Day Avg. Volume64,393
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)5.15
Price to Sales (P/S)6.06
P/FCF Ratio426.90
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$196.67Price Target Upside140.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-7.47
Revenue Forecast (FY)$469.33K
Bulls Say, Bears Say
Bulls Say
Cash Runway And Low LeverageA substantial cash position, combined with total debt below approximately $1.0 million, gives Sol-Gel financial flexibility to advance clinical programs without immediate heavy reliance on borrowing. The planned runway into early 2028 supports continued execution and a measured commercialization strategy.
Phase 3 Clinical ProgressThe pivotal Gorlin syndrome program is progressing toward a defined late-2026 readout, with a reported dropout rate of about 9%. Advancing clinical execution creates a potentially important product catalyst and could strengthen Sol-Gel’s commercial position if the trial supports registration.
Improved 2025 Product EconomicsThe sharp 2025 revenue rebound and gross profit nearly matching revenue indicate that the commercial portfolio can generate attractive product-level economics when sales are present. If sustained, this improvement could support reinvestment, operating leverage, and a path toward better earnings quality.
Bears Say
Persistent Operating LossesSol-Gel remains loss-making despite its 2025 revenue recovery, while cumulative losses have materially reduced the equity base. Continued negative earnings can constrain strategic flexibility and weaken financial resilience unless the company converts clinical and commercial progress into sustained profitability.
Unproven Cash-flow DurabilityThe return to modestly positive cash flow is encouraging, but it follows several years of substantial operating and free-cash-flow burn. That history indicates cash generation is not yet established as a durable capability and could again become a funding concern if improvement reverses.
Revenue VolatilityThe steep year-over-year revenue decline demonstrates that reported performance can be highly uneven and influenced by non-recurring transaction income. This volatility makes the underlying commercial trajectory harder to assess and increases reliance on successful product sales and future pipeline execution.
Sol-Gel Technologies News
SLGL FAQ
What was Sol-Gel Technologies’s price range in the past 12 months?
Sol-Gel Technologies lowest stock price was $23.15 and its highest was $97.97 in the past 12 months.
What is Sol-Gel Technologies’s market cap?
Sol-Gel Technologies’s market cap is $226.50M.
When is Sol-Gel Technologies’s upcoming earnings report date?
Sol-Gel Technologies’s upcoming earnings report date is Nov 05, 2026 which is in 54 days.
How were Sol-Gel Technologies’s earnings last quarter?
Sol-Gel Technologies released its earnings results on Aug 20, 2026. The company reported -$1.13 earnings per share for the quarter, beating the consensus estimate of -$2.36 by $1.23.
Is Sol-Gel Technologies overvalued?
According to Wall Street analysts Sol-Gel Technologies’s price is currently Undervalued.
Does Sol-Gel Technologies pay dividends?
Sol-Gel Technologies does not currently pay dividends.
What is Sol-Gel Technologies’s EPS estimate?
Sol-Gel Technologies’s EPS estimate is -2.2.
How many shares outstanding does Sol-Gel Technologies have?
Sol-Gel Technologies has 3,273,999 shares outstanding.
What happened to Sol-Gel Technologies’s price movement after its last earnings report?
Sol-Gel Technologies reported an EPS of -$1.13 in its last earnings report, beating expectations of -$2.36. Following the earnings report the stock price went down -0.121%.
Which hedge fund is a major shareholder of Sol-Gel Technologies?
Currently, no hedge funds are holding shares in SLGL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sol-Gel Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$196.67 (140.66% Upside)
$196.67 (140.66% Upside)
Blogger Sentiment
Bullish
SLGL Sentiment 100%
Sector Average 62%
Sector Average 62%
Insider Transactions
Bought Shares
Worth $3.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 14.2%
Last 30 Days ▲ 14.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
178.87%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
36.76%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Sol-Gel Technologies
Sol-Gel Technologies Ltd., a pharmaceutical firm currently in its clinical development phase, specializes in the creation and market introduction of skin-applied medications. These products leverage the company's distinctive microencapsulation technology, with their primary development and commercialization activities centered in Israel. Sol-Gel's pipeline features several key candidates. Twyneo, an innovative, non-antibiotic topical cream designed for once-daily application, has successfully concluded Phase III trials for treating acne vulgaris. Similarly, Epsolay, another topical cream administered once a day, has also completed its Phase III studies, targeting papulopustular rosacea. Advancing through Phase I clinical trials is SGT-210, intended for palmoplantar keratoderma. Furthermore, the company is investigating Erlotinib, Tapinarof, and Roflumilast as potential treatments for psoriasis and various other medical conditions. Beyond its proprietary offerings, the company also engages in creating generic versions of topical dermatological medications. Sol-Gel Technologies maintains a strategic partnership with Perrigo. Established in 1997, the company maintains its headquarters in Ness Ziona, Israel.
SLGL Stock 12 Month Forecast
Average Price Target
$196.67
▲(140.66% Upside)
Technical Analysis
Insight Molecular Diagnostics
―
Ovid Therapeutics
―
Shattuck Labs
―
Surrozen
―
Metagenomi, Inc.
―
Ownership Overview
16.86% Insiders
0.04% Mutual Funds
38.18% Other Institutional Investors
44.02% Public Companies and
Individual Investors